De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Mega Lifesciences Toekomstige groei

Future criteriumcontroles 2/6

Mega Lifesciences zal naar verwachting groeien in winst en omzet met respectievelijk 11.7% en 5.4% per jaar. De winst per aandeel zal naar verwachting groeien met 11.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 24.7% zijn.

Belangrijke informatie

11.7%

Groei van de winst

11.6%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	17.2%
Inkomstengroei	5.4%
Toekomstig rendement op eigen vermogen	24.7%
Dekking van analisten	Good
Laatst bijgewerkt	04 Sep 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

SET:MEGA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (THB Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	17,878	2,770	2,626	2,974	6
12/31/2025	16,691	2,543	2,364	2,711	7
12/31/2024	15,813	2,383	2,270	2,814	7
6/30/2024	15,685	1,999	2,400	2,667	N/A
3/31/2024	15,718	2,017	1,915	2,166	N/A
12/31/2023	15,716	1,993	1,633	1,926	N/A
9/30/2023	15,442	1,919	2,297	2,583	N/A
6/30/2023	15,693	2,042	1,773	2,035	N/A
3/31/2023	15,634	2,081	1,798	2,077	N/A
12/31/2022	15,727	2,242	1,684	1,997	N/A
9/30/2022	15,116	2,338	1,327	1,596	N/A
6/30/2022	15,061	2,292	1,852	2,091	N/A
3/31/2022	14,724	2,227	1,800	2,025	N/A
12/31/2021	14,172	1,947	2,567	2,727	N/A
9/30/2021	14,395	1,878	2,302	2,474	N/A
6/30/2021	13,775	1,607	2,289	2,485	N/A
3/31/2021	12,809	1,406	1,932	2,178	N/A
12/31/2020	12,613	1,393	1,374	1,629	N/A
9/30/2020	12,168	1,348	1,487	1,815	N/A
6/30/2020	11,642	1,288	1,122	1,508	N/A
3/31/2020	11,655	1,205	1,271	1,707	N/A
12/31/2019	11,164	1,139	954	1,495	N/A
9/30/2019	10,950	1,163	468	1,406	N/A
6/30/2019	10,712	1,136	275	1,163	N/A
3/31/2019	10,569	1,203	-158	657	N/A
12/31/2018	10,284	1,206	158	910	N/A
9/30/2018	10,147	1,183	429	747	N/A
6/30/2018	9,937	1,175	569	929	N/A
3/31/2018	9,829	1,178	N/A	1,150	N/A
12/31/2017	9,624	1,113	N/A	927	N/A
9/30/2017	9,514	1,023	N/A	967	N/A
6/30/2017	9,282	945	N/A	1,081	N/A
3/31/2017	8,968	873	N/A	1,237	N/A
12/31/2016	8,828	795	N/A	1,250	N/A
9/30/2016	8,514	771	N/A	1,174	N/A
6/30/2016	8,226	756	N/A	920	N/A
3/31/2016	8,115	703	N/A	764	N/A
12/31/2015	7,966	696	N/A	609	N/A
9/30/2015	7,775	675	N/A	825	N/A
6/30/2015	7,862	634	N/A	803	N/A
3/31/2015	7,851	598	N/A	581	N/A
12/31/2014	7,749	548	N/A	614	N/A
9/30/2014	7,620	474	N/A	406	N/A
6/30/2014	7,422	516	N/A	416	N/A
3/31/2014	7,226	567	N/A	473	N/A
12/31/2013	7,055	624	N/A	466	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei MEGA ( 11.7% per jaar) ligt boven de spaarquote ( 2% ).

Winst versus markt: De winst van MEGA ( 11.7% per jaar) zal naar verwachting langzamer groeien dan de markt TH ( 15.3% per jaar).

Hoge groeiwinsten: De winst van MEGA zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van MEGA ( 5.4% per jaar) zal naar verwachting langzamer groeien dan de markt TH ( 6.4% per jaar).

Hoge groei-inkomsten: De omzet van MEGA ( 5.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen MEGA zal naar verwachting over 3 jaar hoog zijn ( 24.7 %)

Mega Lifesciences Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

First half dividend of ฿0.80 announced

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Upcoming dividend of ฿0.80 per share

Final dividend reduced to ฿0.80

Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Now 20% undervalued

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued

Now 21% undervalued

Upcoming dividend of ฿0.80 per share at 3.8% yield

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2023to June 30, 2023, Payable on September 8, 2023

Now 20% undervalued after recent price drop

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Now 25% undervalued after recent price drop

First quarter 2023 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ฿0.85 per share at 3.5% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Upcoming dividend of ฿0.75 per share

Second quarter 2022 earnings: Revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2022 to June 30, 2022, Payable on September 9, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Upcoming dividend of ฿0.86 per share

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited Proposes Dividend for Year Ended December 31, 2021, Payable on April 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ฿0.70 (vs ฿0.39 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of ฿0.52 per share

Second quarter 2021 earnings released: EPS ฿0.58 (vs ฿0.35 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.38 (vs ฿0.37 in 1Q 2020)

New 90-day low: ฿35.50

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ฿1.60 (vs ฿1.31 in FY 2019)

New 90-day high: ฿40.50

New 90-day high: ฿39.00

Third quarter 2020 earnings released: EPS ฿0.39

Revenue and earnings beat expectations

New 90-day low: ฿32.00

New 90-day low: ฿33.00

Mega Lifesciences Public Company Limited (SET:MEGA) completed the acquisition of 83.33% stake in PT Futamed Pharmaceuticals from PT Ersons and others for approximately IDR 180 billion.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven